S-(-)-CarbidopaCAS# 28860-95-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 28860-95-9 | SDF | Download SDF |
PubChem ID | 34359 | Appearance | White crystal |
Formula | C10H14N2O4 | M.Wt | 226.23 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | (S)-(-)-Carbidopa | ||
Solubility | DMSO : 10 mg/mL (44.20 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid | ||
SMILES | CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN | ||
Standard InChIKey | TZFNLOMSOLWIDK-JTQLQIEISA-N | ||
Standard InChI | InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Peripheral decarboxylase inhibitor, used in combination with levodopa for treatment of Parkinsonism. |
S-(-)-Carbidopa Dilution Calculator
S-(-)-Carbidopa Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.4203 mL | 22.1014 mL | 44.2028 mL | 88.4056 mL | 110.507 mL |
5 mM | 0.8841 mL | 4.4203 mL | 8.8406 mL | 17.6811 mL | 22.1014 mL |
10 mM | 0.442 mL | 2.2101 mL | 4.4203 mL | 8.8406 mL | 11.0507 mL |
50 mM | 0.0884 mL | 0.442 mL | 0.8841 mL | 1.7681 mL | 2.2101 mL |
100 mM | 0.0442 mL | 0.221 mL | 0.442 mL | 0.8841 mL | 1.1051 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Carbidopa is an inhibitor of DOPA decarboxylase, which is used in parkinson disease. Target: DOPA decarboxylase Carbidopa (CD), a competitive inhibitor of aromatic l-amino acid decarboxylase that does not cross the blood-brain barrier, is routinely administered with levodopa (LD) to patients with Parkinson disease (PD) to reduce the peripheral decarboxylation of LD to dopamine [1]. CD premedication improves 11C-5-HTP PET image quality and facilitates detection of NET lesions. Because of the similarity of metabolic pathways, this method could probably be applied to improve PET imaging using other tracers like 18F-DOPA and 11C-DOPA [2]. Carbidopa (100 microM) decreased growth of (but did not kill) SK-N-SH neuroblastoma and A204 rhabdomyosarcoma cells and did not affect proliferation of DU 145 prostate, MCF7 breast, or NCI-H460 large cell lung carcinoma lines. sublethal doses of carbidopa produced additive cytotoxic effects in carcinoid cells in combination with etoposide and cytotoxic synergy in SCLC cells when coincubated with topotecan [3].
References:
[1]. Durso, R., et al., Variable absorption of carbidopa affects both peripheral and central levodopa metabolism. J Clin Pharmacol, 2000. 40(8): p. 854-60.
[2]. Orlefors, H., et al., Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging, 2006. 33(1): p. 60-5.
[3]. Gilbert, J.A., L.M. Frederick, and M.M. Ames, The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res, 2000. 6(11): p. 4365-72.
- H-Asp(OBzl)-OBzl.TosOH
Catalog No.:BCC2886
CAS No.:2886-33 -1
- Cediranib (AZD217)
Catalog No.:BCC1121
CAS No.:288383-20-0
- (-)-dicentrine
Catalog No.:BCC8167
CAS No.:28832-07-7
- Lithospermic acid
Catalog No.:BCN5369
CAS No.:28831-65-4
- alpha-Asarone
Catalog No.:BCN3837
CAS No.:2883-98-9
- Denudanolide A
Catalog No.:BCN6522
CAS No.:288259-72-3
- Y-320
Catalog No.:BCC5202
CAS No.:288250-47-5
- Phlorigidoside B
Catalog No.:BCN5189
CAS No.:288248-46-4
- 3,4-Dihydroxyphenylglycol
Catalog No.:BCN5188
CAS No.:28822-73-3
- IBMX
Catalog No.:BCC7502
CAS No.:28822-58-4
- Z-Ala-OMe
Catalog No.:BCC3056
CAS No.:28819-05-8
- SB408124
Catalog No.:BCC4972
CAS No.:288150-92-5
- Z-D-Met-OH
Catalog No.:BCC2758
CAS No.:28862-80-8
- Ergosta-5,24(28)-diene-3,7,16-triol
Catalog No.:BCN5190
CAS No.:289054-34-8
- 3,7,16-Trihydroxystigmast-5-ene
Catalog No.:BCN5191
CAS No.:289056-24-2
- Triazolam
Catalog No.:BCC5218
CAS No.:28911-01-5
- Fmoc-Cl
Catalog No.:BCC2802
CAS No.:28920-43-6
- Anodendrine
Catalog No.:BCN1956
CAS No.:28942-07-6
- Canertinib dihydrochloride
Catalog No.:BCC1449
CAS No.:289499-45-2
- Allo-Thr-OH
Catalog No.:BCC3101
CAS No.:28954-12-3
- Cassiachromone
Catalog No.:BCN5192
CAS No.:28955-30-8
- Oridonin
Catalog No.:BCN5953
CAS No.:28957-04-2
- Lasiodin
Catalog No.:BCN3387
CAS No.:28957-08-6
- Senicapoc
Catalog No.:BCC1943
CAS No.:289656-45-7